asco.org2 天
Real-world data on treatment patterns of advanced CRC in third-line and beyond.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
Cisplatin (Cis) combined with sintilimab (Sint) and niraparib (Nir) in advanced solid ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
Stakeholder evaluation of a supportive care needs assessment tool for adolescent and young ...
Navigating resources associated with school (e.g., talking with advisors, using a disability office) Navigating resources associated with work (e.g., discrimination due to diagnosis, accessing ...
asco.org3 天
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
Choosing Wisely
The American Society of Clinical Oncology (ASCO) is a medical professional oncology society committed to conquering cancer through research, education, prevention, and delivery of high-quality patient ...
asco.org3 天
Assessment of adolescent and young adult oncology patient and provider perspectives in ...
Background: The overall cancer incidence continues to increase in adolescent and young adult patients (AYAs), defined by the National Cancer Institute as individuals diagnosed between the ages of ...
asco.org3 天
Organ-specific responses to nivolumab plus ipilimumab in patients with advanced ...
Background: The Check-Mate 9DW trial demonstrated that combining ipilimumab with nivolumab (Ipi/Nivo) improved survival outcomes compared with sorafenib or lenvatinib in advanced hepatocellular ...
asco.org3 天
An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
Options beyond BRAF targeted therapy in second-line treatment of patients with BRAFV600E ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3 天
Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...